Thrombolysis is a medical treatment that uses drugs to dissolve blood clots obstructing blood vessels. It accelerates the breakdown of the fibrin framework of a clot, potentially restoring circulation before oxygen deprivation causes irreversible tissue damage. Its principal uses include selected cases of acute ischemic stroke, myocardial infarction, and pulmonary embolism. Because it can also cause serious bleeding, its use depends on the diagnosis, time course, expected benefit, and bleeding risk.
Biological mechanism
A thrombus forms through interactions among platelets, vessel-wall processes, and blood coagulation. Coagulation produces fibrin, an insoluble protein network that stabilizes the clot. Although thrombosis may develop where a vessel is obstructed, an obstruction can also result from embolism, in which material travels through the circulation and lodges elsewhere.
The body normally removes fibrin through fibrinolysis. In this process, the inactive precursor plasminogen is converted into plasmin, an enzyme that cleaves fibrin. Most thrombolytic drugs increase plasmin formation, accelerating clot breakdown.
Thrombolysis differs from anticoagulation. Anticoagulants inhibit clotting processes and primarily limit clot extension and new clot formation; they do not directly dissolve an existing clot. Antiplatelet drugs, such as aspirin, reduce platelet activation or aggregation. These treatments may be used alongside thrombolysis in some conditions, but their functions and bleeding risks differ.
Restoring blood flow does not necessarily restore normal tissue function. Benefit depends on how much tissue remains viable, whether small vessels also regain circulation, and whether the underlying obstruction recurs.
Drugs and methods of administration
Thrombolytic agents
Important thrombolytic drugs include:
- Alteplase: a recombinant form of tissue plasminogen activator, which promotes conversion of plasminogen to plasmin, particularly in association with fibrin.
- Tenecteplase: a modified tissue plasminogen activator with a longer circulating half-life, allowing administration as a single intravenous bolus in established treatment protocols.
- Reteplase: another modified plasminogen activator, used principally in myocardial infarction.
- Urokinase: an enzyme that directly activates plasminogen.
- Streptokinase: a bacterial protein that forms an activating complex with plasminogen. Unlike human-derived or recombinant human plasminogen activators, it can provoke immune responses, and pre-existing antibodies may affect its activity.
Availability, approved indications, and preferred agents differ between countries. Greater fibrin specificity does not eliminate the possibility of systemic bleeding.
Systemic thrombolysis
In systemic thrombolysis, the drug is administered intravenously and circulates throughout the body. This approach does not require placement of a catheter within the obstructed vessel, but exposes the wider circulation to its effects.
Catheter-directed thrombolysis
In catheter-directed thrombolysis, a catheter delivers the drug at or within the clot under imaging guidance. It is used in selected venous and peripheral arterial conditions and some cases of pulmonary embolism. Treatment may be combined with devices that fragment or remove clot.
Local administration may permit lower total drug doses, but it still carries bleeding risks and introduces catheter-related risks. Ultrasound-assisted systems are a specialized form; their clinical value depends on the indication and comparator, rather than on clot clearance alone.
Principal clinical uses
Acute ischemic stroke
In ischemic stroke, an artery supplying the brain becomes obstructed. Intravenous thrombolysis can improve functional outcomes in eligible patients when delivered while threatened brain tissue remains salvageable.
Brain imaging, usually computed tomography or magnetic resonance imaging, distinguishes ischemia from hemorrhage and helps assess the extent of injury. Thrombolytic treatment is not a treatment for hemorrhagic stroke.
Conventional eligibility for intravenous thrombolysis commonly extends to 4.5 hours after symptom onset or the last time the person was known to be well. Selected patients with unknown onset or later presentation may qualify through imaging-based protocols. These pathways do not make all later-presenting strokes eligible: imaging findings, symptoms, contraindications, and the applicable protocol remain important.
Mechanical thrombectomy physically removes clot from selected blocked cerebral arteries. It is distinct from thrombolysis, although both treatments may be used in the same patient.
Acute myocardial infarction
Thrombolysis is an established reperfusion treatment for selected patients with acute ST-segment elevation myocardial infarction, usually caused by sudden coronary artery obstruction. Its benefit is greatest early after symptom onset.
Primary percutaneous coronary intervention is generally preferred when it can be performed promptly by an appropriate service. Fibrinolysis remains important when timely intervention is unavailable and eligibility criteria are met. It is commonly considered within the first 12 hours of symptoms, although clinical circumstances and protocols determine applicability.
Thrombolysis is not a routine treatment for non-ST-segment elevation acute coronary syndromes. It also does not remove the underlying atherosclerotic plaque responsible for many coronary events.
Pulmonary embolism
In pulmonary embolism, thrombolysis can rapidly reduce obstruction of the pulmonary circulation and relieve strain on the right side of the heart. Its clearest established role is in high-risk pulmonary embolism with hemodynamic instability, such as persistent hypotension or shock.
Routine systemic thrombolysis is not standard for most hemodynamically stable pulmonary embolisms because the bleeding risk may outweigh the benefit. Systemic, catheter-based, and surgical approaches have different roles in selected severe cases.
Other uses
Thrombolysis may be used in selected cases of acute limb ischemia and extensive deep vein thrombosis. Selection depends on factors including symptom duration, tissue viability, clot location, and bleeding risk.
Small local doses of a thrombolytic drug can also restore patency to some thrombosed vascular access catheters. This is a different clinical setting from systemic emergency reperfusion.
Risks, contraindications, and assessment
Bleeding is the principal complication. It may occur at puncture sites, in the gastrointestinal tract, or in other organs. Intracerebral hemorrhage is especially serious and can cause disability or death. Other adverse effects include allergic reactions, particularly with streptokinase, and angioedema with tissue plasminogen activators.
Common reasons for excluding or restricting treatment include active significant bleeding, certain intracranial conditions, recent major surgery or trauma, and markedly uncontrolled hypertension. Recent anticoagulant exposure and coagulation abnormalities may also affect eligibility. Contraindications are not identical across indications: the risk–benefit balance in immediately life-threatening pulmonary embolism differs from that in other settings.
Assessment incorporates the clinical presentation, imaging, medical history, current medications, and relevant laboratory findings. Monitoring addresses bleeding, neurological changes, circulatory stability, and evidence of successful or failed reperfusion.
Development and evidence
Therapeutic thrombolysis developed from research into natural clot breakdown and bacterial plasminogen activation. Streptokinase and urokinase preceded recombinant tissue plasminogen activators. Large randomized controlled trials established benefits in selected myocardial infarction and ischemic stroke populations, while later studies refined drug choice, timing, imaging selection, and integration with catheter-based treatment.
An important limitation is that opening a vessel is not equivalent to improving survival or functional recovery. Evaluation therefore distinguishes anatomical clot clearance from patient-centered outcomes, including disability, recurrent thrombosis, major bleeding, and mortality. Results from one indication or administration method cannot automatically be applied to another.